How has the dipeptide peptidase 4 inhibitors market evolved, and where is it heading next?
The dipeptide peptidase 4 inhibitors market size has grown strongly in recent years. It will grow from $11.3 billion in 2024 to $11.92 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to improved access to diabetes treatments, expanding indications for DPP-4 inhibitors beyond type 2 diabetes, increasing use of DPP-4 inhibitors in triple therapy regimens, growing geriatric population, increasing focus on healthcare, increasing focus on disease prevention, increasing oral anti-diabetic drugs, and increasing adoption in primary care settings.
The dipeptide peptidase 4 inhibitors market size is expected to see strong growth in the next few years. It will grow to $14.65 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to the increasing prevalence of type 2 diabetes, growing demand for effective diabetes management, aging population in diabetes incidence, increasing focus on personalized medicine, growing adoption of DPP-4 inhibitors in emerging markets, rising prevalence of diabetes and related complications, and increasing demand for diabetes management. Major trends in the forecast period include collaborations, product approvals, and research and development.
Get Your Free Sample of The Global Dipeptide Peptidase 4 Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15791&type=smp
How have varous drivers impacted the growth of the dipeptide peptidase 4 inhibitors market?
The rising prevalence of diabetes is expected to propel the growth of the dipeptide peptidase 4 inhibitors market going forward. Diabetes is a chronic medical condition that affects the way the body metabolizes glucose (sugar), which is a critical source of energy for the body’s cells. Diabetes cases are increasing primarily because of the widespread adoption of sedentary lifestyles and unhealthy eating habits in contemporary societies. Dipeptidyl peptidase 4 inhibitors are utilized in diabetes management to enhance glycemic control by inhibiting the degradation of incretin hormones. For instance, in 2024, according to the International Diabetes Federation, a Belgium-based health organization, 537 million adults (1 in 10) were living with diabetes in 2021, and this is expected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes drives the dipeptide peptidase 4 inhibitors market.
What are the primary segments of the dipeptide peptidase 4 inhibitors market?
The dipeptide peptidase 4 inhibitors market covered in this report is segmented –
1) By Type: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin, Others Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Channels
3) By Application: Type 2 Diabetes, Gestational Diabetes, Metabolic Syndrome, Other Applications
Order your report now for swift delivery
Which firms are leading the dipeptide peptidase 4 inhibitors market?
Major companies operating in the dipeptide peptidase 4 inhibitors market are Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Macleods Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corp., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Lupin Limited, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Limited, Biocon Limited, LG Life Sciences, USV Private Limited, Sanwa Kagaku Kenkyusho Co. Ltd., Kowa Company Ltd
Which geographic trends are shaping the dipeptide peptidase 4 inhibitors market, and which region has the highest market share?
Asia-Pacific was the largest region in the dipeptide peptidase 4 inhibitors market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dipeptide peptidase 4 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Dipeptide Peptidase 4 Inhibitors Market Report 2025 Offer?
The dipeptide peptidase 4 inhibitors market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of drugs used in the treatment of type 2 diabetes by increasing active incretin levels to regulate blood sugar. DPP-4 inhibitors work by enhancing the action of incretin hormones, which stimulate the release of insulin and inhibit the release of glucagon, thereby lowering blood sugar levels.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15791
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
